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Abstract
Background: Previous interventions to increase physical activity and reduce cardiovascular risk factors have been
targeted at individuals with established disease; less attention has been given to intervention among individuals
with high risk for disease nor has there been determination of the influence of setting in which the intervention is
provided. In particular, family practice represents an ideal setting for the provision and long-term maintenance of
lifestyle interventions for patients at risk (ie high-normal blood pressure or impaired glucose tolerance).
Methods/design: The Staged Nutrition and Activity Counseling (SNAC) study is a randomized clustered design
clinical trial that will investigate the effectiveness and efficacy of a multi-component lifestyle intervention on
cardiovascular disease risk factors and vascular function in patients at risk in primary care. Patients will be
randomized by practice to either a standard of care lifestyle intervention or a behaviourally-based, matched
prescriptive physical activity and diet change program. The primary goal is to increase physical activity and
improve dietary intake according to Canada’s Guides to Physical Activity Healthy Eating over 24 months. The
primary intention to treat analysis will compare behavioral, physiological and metabolic outcomes at 6, 12 and
24 months post-randomization including estimation of incident hypertension and/or diabetes.
Discussion: The design features of our trial, and the practical problems (and solutions) associated with
implementing these design features, particularly those that result in potential delay between recruitment, baseline
data collection, randomization, intervention, and assessment will be discussed. Results of the SNAC trial will provide
scientific rationale for the implementation of this lifestyle intervention in primary care.
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The epidemic of sedentary lifestyle and poor eating
habits, with associated escalation of cardiovascular dis-
ease and risk factors, has challenged researchers to
develop new strategies aimed at preventing these grow-
ing health problems [1]. Efforts to prevent the morbidity
and mortality of these chronic diseases as a result of
poor lifestyle have focused mainly on the clinical man-
agement of individuals with existing disease. Such an
approach does not address the potential reversible
causes of these conditions, primarily poor lifestyles
including low levels of physical activity and poor dietary
habits.
Elevated blood pressure and elevated blood glucose
are prototypic of preventable chronic cardiovascular dis-
ease risk factors [2]. Both are common conditions repre-
senting approximately 5-25% of the adult population.
However, many more individuals are at risk [3]. For
example, there is an estimated 90% lifetime risk for the
development of hypertension among those with high-
normal blood pressure [3]. Recent evidence has shown
the importance of lifestyle interventions for the preven-
tion of type-II diabetes amongst individuals with
impaired glucose tolerance, and high-normal blood pres-
sure and hypertension [4-7]. Hence, the unprecedented
epidemic of cardiovascular risk amongst Canadians
which parallels a growing aged, sedentary, and over-
weight population, has occurred despite the unequivocal
evidence supporting lifestyle for the prevention of cardi-
ovascular disease. The result is an urgent need for the
investigation and delivery of evidence-based strategies to
improve lifestyle behaviour resulting in acute and sus-
tainable changes in cardiovascular function and health.
To have maximal impact in preventing further disability,
we will target those patients with preclinical risk for car-
diovascular morbidity (namely those with high normal
blood pressure and/or impaired glucose tolerance). The
catalyst for this bench-to-bedside model will be the
family physician, who will deliver this research interven-
tion in his/her practice to a representative population of
adults at risk.
Rationale for our intervention
T h eF r a m i n g h a mH e a r tS t u d yf o u n dt h a ti n d i v i d u a l s
with high normal blood pressure were 2-3 times more
likely to regress to hypertension than those with optimal
blood pressure [3]. In fact, 37% of individuals with high
normal blood pressure progress to hypertension over a
four-year follow up. Particularly disturbing, in terms of
prevention, is the trend for progression to hypertension
being worse over the last 20 years compared to the per-
iod of 1952-1975 suggesting that an aging, more obese
and sedentary population is placing the burden at
epidemic levels. Epidemiological research in type 2
diabetes (T2D) shows a relative risk of death from car-
diovascular causes compared to non-diabetic age-
matched control ranges from 1.5 to 2.5 higher in men
and 1.7 to four times higher in women [8]. Further,
the rates of cardiovascular morbidity in diabetics can
even be higher and exacerbated by increasing age
where impact can be at 20 times greater risk of coron-
ary heart disease compared to non-diabetic controls
[9,10]. The risk of coronary heart disease events has
increased even in newly diagnosed T2D, probably due
to latent period of impaired glucose tolerance during
which atherogenic effects, including endothelial dys-
function, contribute to a “ticking clock” phenomenon.
T h ee p i d e m i co fT 2 Dp a r a l l e l sh y p e r t e n s i o np r e v a -
lence being clustered in an aging, obese, and sedentary
population and the coexistence of hypertension,
impaired glucose tolerance and diabetes have devastat-
ing consequences despite the unequivocal evidence
supporting the impact of lifestyle interventions.
Indeed, recent studies have shown that lifestyle inter-
vention alone, or even compared to glucose modifying
medications, is effective in preventing the development
of type-II diabetes in those with impaired glucose tol-
erance [4,5]. Further, physical activity and diet have
been shown effective in treating hypertension and T2D
including amelioration of vascular to end-organ
changes [11]. These population trends in the face of
g r o w i n gp r e v e n t i v ee v i d e n c es u g g e s tt h e r ei sa nu r g e n t
need for the implementation of preventive lifestyle
strategies to impact the epidemic of cardiovascular
risk [12]. The approach of waiting for hypertension or
T2D to develop and only then to treat pharmacologi-
cally is contrary to best evidence, best practice, and is
injudicious. Stammler noted that current practice in
prevention is late, defensive, reactive, time-consuming,
associated with side effects, and noncompliance, costly,
only partially successful and endless [13].
Given the high burden of cardiovascular disease in the
population, where is intervention targeted? Family prac-
tice is the ideal setting for a lifestyle intervention, parti-
cularly in the long-term, since there is a continuity of
care required for long-term success, there is promotion
and complimentary preventive health strategies for car-
diovascular health in place. There is also great potential
for interaction with a large population at risk, and
patients identify their family doctor as a preferred
source of lifestyle information [14]. The Canadian health
care system and family practice, in particular, provide
the ideal framework through which to implement life-
style changes among patients at risk since family physi-
cians are the point-of-entry and provide continuity
within the health care system.
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information, prevention and promotion, and an impor-
tant point of contact and influence for Canadians, it is
paradoxical that for the most part, family physicians do
not counsel or monitor lifestyle habits [15,16]. In fact,
family physicians believe in the merits of increased phy-
sical activity and approving diet among their patients,
yet very few counsel or provide written instruction for
their patients regarding the support and health beha-
viour [17,18]. The reasons for this discrepancy are many
and include lack of time, training, and tools [19]. A suc-
cinct message and strategy from the family physician
could be a potent catalyst to motivate changes and life-
style habits among patients. However, the message in
terms of lifestyle intervention in primary care has been
sparsely investigated to date and, specifically, has not
been addressed among those at high risk for hyperten-
sion and T2D [15,20].
Since 1993, the U.S. and Joint National Committee on
the detection, evaluation, and treatment of high blood
pressure and the working group report on primary pre-
vention of high blood pressure have recommended life-
style modifications for blood pressure control, including
weight loss if overweight, sodium reduction, increased
physical activity, and limited alcohol consumption
[21,22]. Similar recommendations have been made for
T2D [23]. Based on the results of dietary approaches to
stop hypertension, the 7
th Report of the Joint National
Committee and the recent Canadian Hypertension Edu-
cation Program have also specifically recommended the
DASH diet, which includes a diet rich in fruits, vegeta-
bles, and low fat dairy products with an emphasis on
reduced overall saturated fat and total fact and choles-
terol content [24-26]. While the DASH diet has been
shown effective in reducing blood pressure, little is
known about the effectiveness of simultaneously imple-
menting different lifestyle recommendations at the same
time (i.e. physical activity and a health diet) nor has the
impact of this and other lifestyle interventions when
implemented at the level of primary care been described
[20]. Indeed, most trials that have studied the effects of
lifestyle interventions on blood pressure and blood glu-
cose have tested the impact of just one lifestyle change
in isolation and few trials have tested the effects of
multi-component interventions simultaneously [27,28].
Since recommendations support lifestyle and some
have gone as far as to endorse specific program inter-
ventions, it is notable that no trial has tested the impact
of these interventions and free-living persons selecting
their own diet or physical activities nor have they under-
gone the rigor of testing in the primary care setting [24].
Studies done in primary care could test or trigger disse-
mination and implementation more globally among lar-
ger populations at risk.
Challenges with the intervention
Behaviour staging using the principles of the trans-
theoretical model has not been considered in many life-
style intervention trials [29]. This in turn may have had
impact on the long-term sustainability of changes that
were observed. Previous lifestyle trials have also not
consistently standardized the measurement or prescrip-
tion of physical activity or dietary behavior [27,30-34].
Further, there has also been a lack of matching of physi-
cal activity to other lifestyle habits, such as dietary
intake. Finally, whether theo b s e r v e dc h a n g e si nb e h a -
viour and clinical outcomes are related to changes in
basic physiological mechanisms that control health is
also essential to understanding the impact of these
interventions on the pathophysiology of hypertension
and T2D.
In this setting of an epidemic of cardiovascular disease
and poor lifestyle, the overall aim of the Staged Nutri-
tion and Activity Counseling trial (SNAC) is to deter-
mine the blood pressure and blood glucose lowering
effects of a matched or scaled physical activity and diet-
ary lifestyle intervention among persons with high nor-
mal blood pressure and/or impaired glucose tolerance.
Further, as most of these patients are seen in family
practice, and given the key role family physicians may
provide in achieving and sustaining lifestyle change, the
intervention will be delivered compared to the usual
care of family practice lifestyle management. Finally, few
studies have suggested that lifestyle interventions (pri-
marily single interventions) can improve physiological
determinants of cardiovascular function and health
[35,36]. Whether this is similar in a large primary care
intervention with two simultaneous lifestyle interven-
tions is unknown. It is anticipated that the results of
SNAC will provide scientific rationale and guidance for
the implementation of this important lifestyle interven-
tion program designed to prevent hypertension and
T2D among those at risk for cardiovascular disease.
Methods/Design
The delivery of the SNAC protocol within the family
practice unit using a brief 10-15 minute intervention
geared to fit within a normal clinic session is critical to
the potential implementation of the intervention in
family practice. This follows previous developmental
work with the STEP intervention which was found to be
effective and acceptable to family physicians [19,37].
Training for the intervention will include a 30-minute
workshop that promoted a team approach to identifica-
tion of patients and delivery of the intervention by the
family physician. The unit of analysis in SNAC is the
individual patient, while the unit of randomization is the
practice itself. Hence, it was deemed necessary to con-
sider a cluster randomized, controlled design to
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SNAC have been endorsed by the College of Family
Physicians of Canada.
The aim of this paper is to describe the design, fea-
tures, and practicalities of the trial that may be common
to other cluster randomized trials within a primary care
setting.
Design
SNAC is a multicentre, cluster-randomized trial. Partici-
pating sites will include 20 clinical centres (6 academic
family practices and remaining 14 non-academic cen-
tres). The Heart, Health, and Exercise Laboratory at the
University of Western Ontario will serve as the central
laboratory for all physiological and biochemical collec-
tions, and analyses. Recruitment of all clinical sites has
been previously described with a catchment of over
150,000 patients [38]. The diet assessment and composi-
tion of the Mediterranean diet choices will be coordi-
nated through Brescia College School of Nutrition at
the University of Western Ontario, including quantifica-
tion of dietary consumption using Food Processor (v
1.0). Serum measurement of free fatty acid levels (under
the supervision of Dr Bruce Holub, University of
Guelph) and measurement of endothelial markers of
vascular function will be processed in the lipid analysis
laboratory at McMaster University. Plasma leptin levels
will be measured in the laboratory of Dr. Peter Lemon
at the Exercise Nutrition Laboratory at the University of
Western Ontario. The study has been funded by the
Heart and Stroke Foundation of Canada and was
approved by the Institutional Ethics Review Board of the
University of Western Ontario.
Study Population
Primary care practices will be recruited using a family
practice research network. Randomization to interven-
tion or usual care control will be done by a random
number table. Recruitment of patients within the prac-
tices will include two successful strategies previously uti-
l i z e db yo u rg r o u pi n c l u d i n gopportunistic recruitment
of consecutive patients during the course of routine,
prescheduled, clinic visits or query of the network data-
base for inclusion criteria and screening of patient visit
lists [19,37]. All practices will target 10-12 patients each
over a 6-month period.
Intervention under trial
Content of intervention We based the content of the
intervention on recommendations for dietary and physi-
cal activity lifestyle management made by several sys-
tematic reviews and recommendation processes
[23,24,26,39,40]. These were supplemented by our own
experience and success using the STEP program for
physical activity adoption among primary care
physicians [37]. Further refinement has included the
piloting of the SNAC diet activity prescription among
representative groups of patients [41]. Resource materi-
als and training for those in the intervention group will
be facilitated by dieticians including the development
and delivery of grocery tours, cooking demonstrations,
as well as meal preparation and menus according to
Mediterranean style diet [42]. A training package for
physicians has been prepared to assist in standardizing
the implementation of SNAC materials in their practice.
A workshop will provide skills and behaviour staging in
diet and physical activity counseling and prescription.
Patients will be staged separately for both physical activ-
ity and dietary change readiness and then asked to per-
form an exercise step test to determine exercise training
heart rate and activity diet prescription for each patient
[43]. Determination of fitness within each subject will be
translated into a low, moderate, or high category when
compared to population averages and this will be trans-
lated into the prescription of specific consumption of
recommended fruits, vegetables, grains, meat products,
and using a Mediterranean diet algorithm [44]. A selec-
tion of resource materials matched for stage of readiness
in terms of their content for increasing physical activity
levels, as well as adopting the Mediterranean diet by
subjects will be provided to participating physicians and
staff during a workshop. Key items for review at each
study visit will be highlighted to promote adherence and
to prevent drop out during the clinical trial period.
Patients will be eligible if they have had high normal
blood pressure determined as a seating resting systolic
blood pressure between 130 and 139 mmHg and/or a
diastolic blood pressure of 85-90 mmHg based on aver-
age of three repeated blood pressures, and impaired glu-
cose tolerance determined as a fasting glucose level
between 6 and 6.9 mmol/l plus a 2 hour post 75 glucose
challenge of 8-11 mmol per litre. Patients with hyper-
tension or T2D will be excluded. Other inclusion cri-
teria will include age from 30-85 years, willingness to
participate in the interventions and participation over a
12-month period and the presence of High-normal
blood pressure or IGT/IFG. Exclusion criteria will
include: Myocardial infarction within 3 months prior to
study; Coronary artery bypass within 3 months prior to
study; Cerebrovascular ischemia/stroke within 3 months
of study (including TIA); Previous (>6 months) diagno-
sis of hypertension or T2D; Angioplasty within 3
months of study; Symptomatic congestive heart failure;
Atrial flutter, presence of controlled or uncontrolled
hypertension: Unstable angina: Unstable pulmonary dis-
ease (e.g. asthma or obstructive lung disease); Use of
medications know to affect heart rate (e.g. b-blockers);
Second or third degree heart block, History of alcohol-
ism, drug abuse, or other emotional, cognitive or
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to the study; Pacemaker; Unstable metabolic disease (e.
g. uncontrolled diabetes glucose >15mmol at screening);
Orthopedic or rheumatologic disease (i.e. severe rheu-
matoid arthritis); Known Autonomic Nervous System
Disorders such as Raynaud’s Syndrome or Autonomic
failure; Already enrolled in clinical research trial.
Randomization
Eligible practices will be randomly assigned to either
SNAC or usual care control by a computer program. All
practices in the intervention group will attend a training
session as described above, while the usual care group
will attend a sham hypertension guidelines training pro-
gram. Both training sessions will be matched for
duration.
Eligible participants who provide informed consent
will attend a baseline visit for data collection. At this
visit, patients will be prescribed a lifestyle program
either SNAC or usual care. In the SNAC intervention,
patients will be staged and the activity:diet prescription
will be delivered. Those in SNAC will receive stage-
matched resources, schedules for cooking demonstra-
tions and grocery tours, and consultation appointment
cards for study kinesiologists or dieticians. Both groups
will be given study visit schedules. The visit schedule is
provided in Table 1.
Blinding
Clinical centre staff at the Heart, Health and Exercise
Laboratory will be blinded throughout the trial.
Interventions
The theoretical basis for the SNAC intervention is mod-
eled within the social cognitive theory and transtheoreti-
cal stages of change. This approach emphasizes the
importance of an individual’s ability to regulate their
own diet and activity behaviour by setting goals, moni-
toring progress towards these goals, and attaining the
necessary skills to reach these goals. These approaches
also seek to increase the self-efficacy and outcome
expectancies both of which are critical mediators of
behaviour change. The transtheoretical model also
recognizes that behaviour change is a dynamic process.
Different behaviour strategies may be emphasized
depending on the individual stage of readiness for
change. In addition, the SNAC intervention also empha-
sizes motivational counseling techniques. Input from all
members of the family practice team including kinesiol-
ogists and dieticians will be enlisted as would be the
case in usual care practice. Further, behaviour change
will be targeted through a tailored diet:activity prescrip-
tion. Hence, the theoretical basis for SNAC contrasts
sharply with the delivery of lifestyle modifications in the
usual clinic settings, which rely primarily on verbal
advice without attention to specific diet:activity targets
within individuals nor do they attend to behaviour
change or referral to allied health specialists [15,16].
This would support the approach patients would prefer
and what best evidence suggests is most effective
[16,17].
Schedule of visits
After initial baseline assessments, patients will be coun-
seled to adhere to their new physical activity and dietary
recommendations over the next three months. Follow
up in this 3 month block includes unencumbered access
to the study physician as well as to a dietician and/or
kinesiologist in the coordinating centre. To facilitate
adoption of a Mediterranean diet, one meal per day
(5 days per week) will be offered to patients by the Uni-
versity of Western Ontario Food Services Program or
Table 1 Schedule of Observation and Procedures
Assessment Screening Baseline Week 8 Week 16 Week 24 Week 52 Final Visit
Informed Consent X
Medical history X
Physical exam X
Randomization X
Clinical Blood Pressure X X X X X
24 hour ambulatory blood pressures X X X X X
Fasting glucose/blood profile X
2 hour glucose tolerance test X
Physical Fitness X X X X
Behavioural Measures X X X X
Physiologic Measures X X X X
Drug X X X
Placebo X
Petrella et al. Trials 2011, 12:45
http://www.trialsjournal.com/content/12/1/45
Page 5 of 11for the first eight weeks of the program. This will serve
to familiarize the subjects with the quantity but also the
quality of the Mediterranean diet. Since this approach
does not provide all meals, we do not believe this would
influence our clinical or physiological outcomes in the
longer term. Patients will be advised to collect 3-day
food records prior to their next visit as well as to log
their physical activity behaviours. At each 3-month
interval, the patients will return to the family practice to
have repeat measures done including diet:activity resta-
ging and a new diet:activity prescription. This will be
followed by laboratory assessments of the physiological,
biochemical, and anthropometric measures. The family
physician visit also offers the opportunity to reinforce
activity dietary change.
Study Measurements
Measurements will occur at baseline, 2-months, 6-
months, 9-months, 12-months and 24-months post
intervention (Table 1). Primary and secondary outcome
measures are described as clinical, behavioral and
physiological.
Primary and Secondary Outcome Measures
Primary Outcome Measures
a) clinical - clinic blood pressure with an automated BP
device BPTRU™; fasting glucose, b) physical fitness -
predicted VO2m a xusing STEP test and measured VO2
max using a modified Balke exercise treadmill protocol;
BMI, c) physiological measures: brachial and carotid
artery endothelial flow-mediated dilation and function.
Secondary Outcome Measures
a) clinical - 24-hour ambulatory blood pressure; 2-hour
glucose tolerance testing, hemoglobin A1C, microalbu-
min; waist circumference, calorie counts, b) behavioural
measures - stage of change, self efficacy for diet and
physical activity change, quality of life (SF36), barriers
and benefits scales, c) physiological measures - waist cir-
cumference, calorie counts, dietary composition, cardiac
function (echocardiographic determination of systolic
and diastolic function, and left ventricular wall dimen-
sions and volume), vascular geometry and elastic prop-
erties of the carotid and brachial arteries, muscle
sympathetic and nerve activity discharge patterns at rest
and a response to lower body negative pressure. Blood
chemistry included blood lipid profiles homocystine,
serum insulin, rennin, aldosterone, cortisol, C-reactive
protein (CRP), markers of endothelial function including
vascular adhesion molecule (VCAM) and intracellular
cell adhesion molecule 1 (ICAM-1), urinary catechola-
mines, and serum free fatty acid composition.
Effects dependent on demographic subgroups will be
defined by age, gender, and practice setting. Since pre-
vious trials have suggested that lifestyle interventions
achieve their greatest effects early on, and that effects
tended to diminish over time, we will evaluate the dur-
ability of these effects to 12 months and then for a
further 12 months thereafter to determine the interven-
tion rate of decay.
Sample Size and Data Analysis
Sample Size
Data from a previous “feeding” trials including the
DASH trial have estimated a standard deviation change
in systolic blood pressure after the intervention was
between 5.32 and 5.92 mmHg providing a 90% power
[24]. In terms of change and blood glucose levels, 0.1 to
0.3 mmol. reduction are considered important in differ-
entiation of the risk for the development of T2D [4].
For physiological outcomes’ sample size estimate, we
chose a mean difference between groups of 0.25 mm
standard deviation as appropriate for change in vascular
dimension. Previous work in our laboratory support the
ability to detect the 2 mm difference in vessel diameter
with a standard deviation of .025 mm following a similar
lifestyle intervention. Hence, we required at least 10
subjects per group (two-tailed t-test, p < 0.025, power =
0.8). Assuming an 80% success rate in achieving suitable
recordings in two test sites and a drop out rate of
approximately 20%, we will recruit 40 subjects per treat-
ment arm to the high normal blood pressure and IGT
groups.
Initially, we anticipated recruiting about 5-10 patients
per practice using a cluster design. To allow for the
effect of this clustering we used an interpractice correla-
tion coefficient (ICC) of 0.025. We felt this would be a
conservative upper limit for the ICC on the basis of pre-
vious work in primary care. The inflation factor was
therefore calculated to be 1+0.025 (10 minus 1) = 1.05.
This figure gives a required number of patients per
treatment arm of approximately 90 equivalent to 10
practices recruiting about 10 patients each.
However, there is some theoretical loss of power from
using variable cluster sizes. This is negligible in the cur-
rent study of approximately 50 patients per treatment
arm. Hence, our allocation method of 10 patients per
practice was designed to avoid this possibility. Statistical
analysis will include differences among the subjects’
characteristics in clinical, behaivoural, and physiological
outcome measures using analysis of variance (ANOVA).
Interactions and/or a specific age, gender, or clinical
variable differences will be examined using Tukey’sp o s t
hoc analyses. If a group difference in a potentially con-
founding variable is observed at limit differences in a
key outcome, analysis of covariance (ANCOVA) will be
performed with the potentially confounding variable ser-
ving as the covariant. Relations of interest will be initi-
ally identified by univariate correlation analysis.
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will be determined using partial correlation analyses
and/or conventional multivariate step-wise regression
analysis. In all cases, probability levels will be p < 0.05.
Delivery of Lifestyle
Practical issues arise in the delivery of lifestyle interven-
tions in primary care. Previous pilot work by our group
has identified contamination of controlled practices
could occur, despite using a cluster randomized design.
However, this contamination has been small and would
favour the null hypothesis. Contaminations can include
non-study related public education or public health/phy-
sicians targeting dietary and lifestyle interventions that
occur as “background noise” intended for use in various
clinical settings. We have partnered with local public
health and pharmaceutical industry to minimize the
impact of these contaminations. Contamination could
also arise from patients moving between clinical prac-
tices. This will be negligible in the current trial as all
clinic staff and patients are rostered to the study prac-
tice and cross-coverage between practices is not encoun-
tered. These potential contaminants will be discussed
during the SNAC and control training sessions for study
physicians and staff.
Timing of the Intervention
Pilot work in our lab has demonstrated that it is imprac-
tical to impose strict study start times and recruitment
targets within some practices. Hence, there will be no
particular matching of start times or recruitment activity
between practices. Support will be given to all practices
to increase or maintain their recruiting activities over
the first two months of their involvement in the trial
and given the demands of the clinical settings, all prac-
tices will be encouraged to complete recruitment for the
trial within three months of their enrollment and train-
ing. Our previous work supports anticipated success of
this strategy.
Timing of Recruitment
A key design feature of this trial is that the allocation of
practices within the research network will be carried out
prior to the recruitment of the required number of
patients. This will be done to ensure proper understand-
ing of the trial and review recruitment strategies to
avoid selection bias utilized by our group in a previous
randomized controlled cluster design of physical exer-
cise prescription in primary care [45]. Similar differences
in patient characteristics at baseline between the SNAC
and the control group in this trial allow for valid inter-
pretation of results. We do not anticipate a difference in
recruitment times between the two groups because both
groups will be counseled regarding recruitment
strategies for the trial at the same time. This may be in
contrast to other studies where slow uptake of control
practices have been reported should the treatment allo-
cation be known prior to recruitment. Hence, practices
would potentially see little gain from their participation.
Further, unequal timeframes for recruitment of patients
to the intervention or control groups could bias com-
parison. For example, there is good evidence for seaso-
nal variation on the lifestyle factors of physical activity
and diet. If either of the groups recruited more patients
during a particular season or it was stratified to do so,
then they could be expected to have a change in one of
the lifestyle interventions regardless of the intervention
itself.
Recruitment of Practices
This trial was designed to include practices in South-
western Ontario, which has a higher burden of cardio-
vascular disease than other parts of the province [44].
We have aimed to recruit a total of 20 practices to the
trial with stratification for urban, rural, and academic
practice affiliation distribution. We then would obtain a
representative balance of practice settings within the
region.
Recruitment of Patients
It will be the responsibility of each participating practice
and not the research coordinating centre staff to recruit
consecutively attending patients with high normal blood
pressure and/or impaired glucose tolerance within the
selection criteria. Any member of the primary care team
can recruit patients. It is anticipated the process would
be completed within 2-3 months of enrolment into the
program. Delay in recruitment of some practices, due to
unforeseen changes in the practice environment includ-
ing staff leave, vacations, and competing interest in
other clinical trials, will be minimized given the estab-
lished activity of the research network. For example,
once a practice has recruited its quota of patients, the
strategy used to achieve this quota will be shared with
those in the same intervention group by the research
staff. No incentives will be utilized as this will not be
the case in usual practice. It is apparent that some
patients, given the nature of the intervention and assess-
ments, will drop out before the baseline data collection.
If this recurs, every effort will be made to replace the
patient prior to the randomization. In addition, there is
a possibility that some patients will have an exacerbation
of their blood pressure or blood glucose through the
randomization phase requiring other forms of treatment.
This will be treated as an exclusion for the study and
patients will be withdrawn. This will not lead to a bias
in comparison to the intervention and control arms as
both groups will be subjected to the same risk. Whether
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tion and control situations to general practices is also
not an issue as many patients with high normal blood
pressure or impaired glucose tolerance will convert to
hypertension or T2D at any point in time. Record of
those who are withdrawn from the protocol at any point
will be analyzed to identify other aspects of prevalence
of these conditions and determinants of adherence
within the family practice settings.
The non-random selection of practice patients within
the study practices could have impact on the generaliz-
ability of the results of this trial. However, this is stan-
dard in most randomized clinical trials, whereby
convention, patients in participating centres are selected
systematically rather than randomly. Implementation of
the findings of randomized, controlled trials is an
important area of research by our group. Importantly,
practices in this trial will be balanced for a practice set-
ting (academic, rural, urban) and will enhance the gen-
eralizability of the communities they represent in the
future implementation of dissemination strategies.
Treatment allocations
Timing
In an ideal world, patients in this trial would be
recruited, provide consent, and physicians/researchers
would obtain a baseline clinical data collection in the
morning followed by laboratory assessments within the
next 24 hours for completion of the clinical, beha-
vioural, and physiological measures. In a trial such as
ours in primary care, however, each of these stages
takes a variable amount of time, planning, and schedul-
ing within each practice. We have designed the trial in a
way to ensure that each stage takes place as quickly as
possible after the previous stage (within one week) so as
to avoid the potential problems of patient drop out or
change in physiological and clinical variables over a
longer period of time.
Recruited patients will be consented in their practice
setting while baseline clinical, behavioural and physiolo-
gical measures will be collected in the Heart, Health &
Exercise Laboratory. Patient data will be monitored for
completeness by independent assessors to ensure blind-
ing of outcome measurements.
Outcome Assessment
Blinding of patient outcome assessment is possible with
a lifestyle intervention targeted at practice level as the
patient only assumes they are receiving lifestyle inter-
vention by their family physician as part of a treatment
program in a research study and is not aware of the
intensity of the intervention vs. a usual care control.
Further, as the assessors within the central laboratory
are also blinded to the treatment, this will help to main-
tain the blind. We will request that individual practices
not discuss the trial with colleagues and other practices
in an attempt to minimize bias and contamination.
Methodological Considerations & Limitations
The structure of primary care practice in Canada is one
of a nested hierarchy with patients grouped within pri-
mary care practices, some of which are within primary
care groups within local health authorities. It was inevi-
table within this setting that cluster-randomized control
trials were used to assess our new mode of lifestyle ther-
apy. As cluster randomized trials are becoming more
common, it is worth considering some of the practical-
ities of such a trial design in the field of lifestyle inter-
vention of this particular project.
The first issue identified during pilot work was that
of potential contamination. Although general practi-
tioners tend to “nest” within practices, many other
health professionals and staff may move through multi-
ple practices. This was not the case within the current
research network; however, this could be an area of
concern for wider intervention dissemination. If this
potential contamination is ignored however this could
lead to dilution of estimates of intervention effect. A
second issue stems from the potential slow recruitment
of patients in some clusters. While recruitment rates in
this trial and previous trials in our experience have
been quite good and given that recruitment has to
occur prior to randomization in order to prevent bias
within individual patients as opposed to practice, this
could lead to a lack of incentive among some patients
for participation. Further, the resulting delay between
recruitment and allocation times allow for patient
withdrawals and for conversion of patients to hyper-
tension and T2D which may affect comparability
among subjects. Patient withdrawal prior to allocation
to intervention however will not bias results, but sam-
p l es i z ee s t i m a t e sm a yn e e dt ob ei n f l a t e dt ot a k ei n t o
account the number of patients recruited who are not
eligible at randomization either due to conversion to
the clinical syndrome or due to simple withdrawal.
Early patient recruitment has several advantages as
well as several disadvantages. The large number of
patients involved may be a limit to the accommodation
of patients involved in clinical trials within the con-
straints of general practice. However, given that the
current study only required 10 patients per practice,
this is a relatively small-added time burden to the
recruited practices and was not a key concern. It is not
our experience that cluster randomized trials in pri-
mary care require any additional time or financial sup-
port as compared to single centre randomized
controlled trials. In fact, since these studies tend to
reflect the usual care within practice, cluster randomi-
zation seems to ideal to allowing all patients and
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discrimination or necessarily added time/resource
burden.
Discussion
The health benefits and implications of the SNAC life-
style intervention could be substantial. In patients with
a high risk for hypertension and T2D, each component
of the SNAC intervention, including increasing physical
activity and alteration of dietary intake, have been
shown to reduce blood pressure and blood glucose in
previous studies. However, a lack of implementation of
these interventions using tailored primary care
approaches has restricted the impact. The net effect of
these small improvements in clinical variables can have
quite significant effects on the prevention of hyperten-
sion and T2D, and hence cardiovascular risk [46].
Hence, the effects of the SNAC intervention on cardio-
vascular outcomes could be impressive.
It has been suggested that a population-wide approach
of the DASH dietary pattern could reduce the incidence
of coronary heart disease by 15% and stroke by 27% in
U . S .a d u l t sj u s tf r o mB Pr e d u c t i o na l o n e[ 4 7 ] .W es u g -
gest that the net effect of SNAC could be substantiately
greater due to a combined lifestyle intervention but also,
since the adherence and implementation to such a pro-
gram could be greater through delivery in a family prac-
tice setting this seems even more likely than was
observed in previous studies [48]. Further, we will iden-
tify the underlying behavioral and physiological determi-
nants of these clinical changes. This will improve our
understanding of the global improvement in patient car-
diovascular risk.
Several aspects of the SNAC trial design and interven-
tion strategy are also noteworthy. Firstly, SNAC will
testing the recommendations of several policy-making
organizations for cardiovascular health. These generally
include adoption of low to moderate levels of physical
activity, but in this trial using an exercise prescription,
the adoption of higher levels of physical exercise to
improve fitness as has been recommended for optimal
cardiovascular benefit will be tested [49]. We also
include the specific adoption of heart-healthy Mediterra-
nean diet that is matched to level fitness of the indivi-
dual regarding changes in blood pressure, glucose,
behavioural and physiological indices [42]. This has not
been reported to date. The exercise and diet prescrip-
tion adherence will be enhanced through behavioural
lifestyle modification such that tailored support will be
delivered as a component of the SNAC prescription.
Secondly, few trials to date have tested the effects of a
comprehensive lifestyle modification within family prac-
tice and none to our knowledge have studied a matched
exercise diet prescription. This is important as family
practice is identified as the optimal delivery system and
preferred source for adoption and maintenance of
health lifestyles in the longer term. Most previous trials
have attempted to isolate the effects of specific out-
comes like blood pressure or blood glucose on single
factors, such as weight loss alone or physical activity
alone, rather than combining factors that is certainly
relevant to the patients in the primary care setting. This
makes sense. While the efficacy of the DASH diet has
been demonstrated in controlled studies, this has not
been demonstrated in free-living individuals or a deliv-
ery system such as in primary care where optimal con-
tact with patients at risk will be observed. Hence,
SNAC offers an opportunity to determine the extent to
which community living individuals in primary care can
adhere to a lifestyle intervention along current
recommendations.
Comparison of the SNAC intervention with the usual
care control will help to give comparison of usual clini-
cal practice towards lifestyle intervention in primary
care. Hence, we will be able to test our survey data sug-
gesting low levels of physical activity prescription are
performed in primary care [16]. While a significant dif-
ference between the two arms in this study are antici-
pated and would provide further support for public
health policy advocating adoption of healthy lifestyles
including those prescribed using SNAC, a finding of no
significant difference between these interventions would
also provide important information. Such a result may
reflect either no true difference between groups in
which case improved lifestyle counseling of usual care
may be very effective when observed in the research set-
ting. An alternative view may be that there was an
inability of participants to make changes as suggested in
the SNAC intervention. Regardless of outcome, addi-
tional insight into the observed results will come from
secondary analysis that will document the extent to
which participants were able to achieve the intervention
targets for clinical, behavioural, and physiological out-
comes in the short as well as long-term.
An important design consideration has been the inclu-
sion of blood pressure measurement technique using an
automated device. This technique would reduce the
measurement bias as well as provide standardization of
technique between practices which may not have been
the case in previous studies. This will be corroborated
using 24-hour ambulatory technology. The inclusion of
persons with above optimal, but not hypertensive blood
pressure is a significant population at risk at a time
when lifestyle mediated intervention can significantly
reduce the blood pressure-related and glucose-related
cardiovascular morbidity and mortality. Linking clinical,
behavioral and physiological outcomes in this study is
truly translational research at the point of care.
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pertaining to the implementation of lifestyle recommen-
dation in the comprehensive management of patients
with early cardiovascular risk as well as those with
established risk factors [17]. Despite regular, widely dis-
tributed guidelines suggesting the importance of lifestyle
modifications of basis for therapy and prevention, imple-
mentation of such guidelines into routine medical prac-
tice has been suboptimal. At present, implementation
relies on physicians without training, interventions or
tools. This presents barriers to delivery that will be
directly addressed in the current trial where physicians
will be provided with validated, tailored clinical practice
tools developed for their setting. This would be particu-
larly important to contemporary health care systems
such as managed care organizations, who offer specia-
lized health education and prevention programs as well
as newly implemented family health care teams in
Ontario, who could potentially implement such pro-
grams as SNAC for global cardiovascular risk prevention
and control. These programs are currently reimbursed
by health insurance and are provided in both fee-for-
service settings, as well as managed care organizations.
Hence, there is a precedent for implementation of the
SNAC lifestyle intervention to control and prevent car-
diovascular disability.
In summary, it is anticipated that the results of the
SNAC trial will provide scientific rationale in support of
an evidence-based multi-component lifestyle interven-
tion program designed to reduce the risk of hyperten-
sion and T2D at the primary care level. Translation of
clinical and laboratory based physiological measures will
help establish the validity of these findings as an impor-
tant part of preventive practice for family physicians.
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